Trajenta Linagliptin Tablets

1. Indications and Usage
Monotherapy: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Combination Therapy: Used in combination with metformin, pioglitazone, or insulin when appropriate for the patient.
2. Dosage and Administration
Recommended Dose: The usual dose is 5 mg once daily, taken orally without regard to meals.
Renal/Hepatic Impairment: No dosage adjustment is necessary for patients with renal impairment, including those on dialysis, or with hepatic impairment.
Missed Dose: If a dose is forgotten, it should be taken as soon as possible on the same day. If it is not remembered until the next day, the dose should be skipped.
3. Mechanism of Action
DPP-4 Inhibition: Linagliptin is a potent, highly selective, and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4).
Incretin Regulation: It inhibits the inactivation of incretin hormones (GLP-1 and GIP), leading to increased plasma concentrations.
Glucose-Dependent Effects: Elevated incretin levels enhance glucose-dependent insulin secretion and suppress glucagon release from the liver, thereby lowering blood glucose levels.
4. Safety and Warnings
Heart Failure: Post-marketing cases of heart failure have been reported with DPP-4 inhibitors. Patients should be monitored for signs and symptoms, and the drug discontinued if they occur.
Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported. If suspected, discontinue immediately.
Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative skin conditions (e.g., Stevens-Johnson syndrome), have been reported.
Bullous Pemphigoid: Blistering skin conditions have been reported with DPP-4 inhibitors; patients should be advised to discontinue the drug if blistering occurs.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: Nasopharyngitis, headache, diarrhea, and cough.
Hypoglycemia: Low risk as monotherapy, but the risk increases when used in combination with sulfonylureas or insulin.
Other Adverse Effects: Hypersensitivity reactions, arthralgia, and rash.
Clinical Findings: Clinical trials have demonstrated significant reductions in HbA1c and fasting plasma glucose with a low incidence of hypoglycemia.
6. Drug Interactions
CYP450 Enzymes: Linagliptin is extensively metabolized by CYP3A4/5 to the active metabolite, but it does not inhibit or induce these enzymes.
P-gp Substrates: Linagliptin is a substrate of P-glycoprotein (P-gp). Concomitant use with P-gp inducers or inhibitors may affect its exposure, but clinically significant interactions are unlikely.
Hypoglycemic Agents: Concomitant use with insulin or sulfonylureas increases the risk of hypoglycemia.
Other Agents: No significant interactions with metformin or pioglitazone have been observed.
7. Pharmaceutical Information
Active Ingredient: Linagliptin.
Strengths: Typically available as 5 mg tablets.
Appearance: Film-coated tablets, typically orange to pinkish-orange.
Storage: Store at controlled room temperature (20°C to 25°C) in a dry place, protected from light and moisture.